Kiora Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.6%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.67next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 6 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2KTarget: Late 2028
ABACUS-2 Phase 2 Trial Enrollment QuarterlyTarget: Complete enrollment of 36 patients
KLARITY Phase 2 Trial Enrollment QuarterlyTarget: Complete enrollment of up to 28 patients
Watch Items
- ABACUS-2 Phase 2 clinical trial initial data readout for KIO-301Trigger: Q3 2027Action: Evaluate efficacy and safety profile of KIO-301 in retinitis pigmentosa patients to support progression to registrational trials.
- KLARITY Phase 2 clinical trial initial data readout for KIO-104Trigger: First Half of 2027Action: Assess reduction in retinal macular edema and safety profile to determine next clinical development steps.
- Senju Pharmaceutical option exercise for Asian rightsTrigger: Milestone achievement or option expirationAction: Secure up to $110 million in potential deal value plus royalties upon option exercise.
Research as of 20 Jun 2026